novartis ag-sponsored adr (NVS:New York)
Transactions by NOVARTIS AG-SPONSORED ADR (NVS) in the last 6 months
Aduro BioTech, Inc. announced that it has received $25 million in a round of funding from new investor Novartis AG on March 30, 2015. As a result of the transaction, the investor has acquired 2.7% stake in the company. The investor has also committed to invest another $25 million at a future date,
GlaxoSmithKline plc (LSE:GSK) acquired 4.96% stake in Valneva SE (ENXTPA:VLA) from Novartis AG (SWX:NOVN) on March 3, 2015.
Caribou Biosciences, Inc. announced that it has received undisclosed amount in series A round of equity funding from Novartis AG on January 7, 2015.
Mission Bay Capital LLC
Intellia Therapeutics announced that it has received $15 million in its first round of funding from new investors Atlas Venture L.P. and the research arm of Novartis AG. on November 18, 2014. Atlas Venture L.P. invested in the formation of the company.
bioCSL Inc. entered into a definitive agreement to acquire influenza vaccines business from Novartis AG (SWX:NOVN) for approximately $280 million on October 26, 2014. The Novartis influenza vaccines unit will be combined with bioCSL. For the year ended December 31, 2013, influenza vaccines business posted sales of $527 million. The transaction requires regulatory approvals and is expected to close in the second half of 2015. Tim Duncan of Hintons & Associates acted as ...
|Gilead Sciences Inc||$101.38 USD||-1.96|
|Johnson & Johnson||$99.58 USD||-0.21|
|Merck & Co Inc||$56.88 USD||-0.96|
|Pfizer Inc||$35.04 USD||-0.15|
|Roche Holding AG||SFr.270.20 CHF||-5.10|
|View Industry Companies|